Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 5-hydroxytryptamine receptor 3A (5-HT3A) is a subunit of the type 3 serotonin receptor, a ligand-gated ion channel mediating fast excitatory neurotransmission in both the central and peripheral nervous systems. Upon activation by serotonin, it forms a cation-selective channel allowing rapid influx of sodium, potassium, and calcium ions, resulting in neuronal depolarization. It is a target for antiemetic drugs like ondansetron and granisetron, and is implicated in psychiatric disorders such as major depressive disorder and PTSD.
Activation by serotonin leads to opening of the cation-selective ion channel, resulting in rapid influx of Na+, K+, and Ca2+ ions and subsequent depolarization. Antagonists block the channel, preventing ion flow and inhibiting neurotransmission.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-hydroxytryptamine receptor 3A (5-HT3A).